Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases

Cancer

Volumn 88, Issue 12 SUPPL., 2000, Pages 2934-2939

  Serafini, Aldo N ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Bone pain; Metastatic cancer; Samarium 153 lexidronam; Systemic radioisotope therapy

Indexed keywords

LEXIDRONAM SAMARIUM SM 153;

ANOREXIA; ASTHENIA; BONE MARROW SUPPRESSION; BONE METASTASIS; BONE PAIN; CANCER PAIN; CANCER PALLIATIVE THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; PAIN ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; SPINAL CORD COMPRESSION; TREATMENT OUTCOME; URINARY TRACT INFECTION;

EID: 0034659856     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20000615)88:12+<2934::aid-cncr9>3.0.co;2-s     Document Type: Conference Paper

References (17)

1. Payne R. Pain management in the patient with prostate cancer. Cancer 1993;71(Suppl):1131-7.
2. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997;69:1-18.
3. Tong D, Gillick L, Hendrickson FR. The palliation of symptomatic osseous metastases. Cancer 1982;50:893-9.
4. Averbuch S. New biphosphonates in the treatment of bone metastases. Cancer 1993;72:3443-52.
5. Coleman RE. Biphosphonate treatment of bone metastases and hypercalcemia of malignancy. Oncology 1991;5:55-62.
6. Conte PF, Latreille J, Mauriac L, Calabresi F, Santos R, Campos D, et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. J Clin Oncol 1996;14:2552-9.
7. Robinson RG, Preston DF, Spicer JA, Baxter KKG. Radionuclide therapy of intractable bone pain: emphasis on strontium-89. Semin Nucl Med 1992;22:28-32.
8. Winston MA. Radioisotope therapy in bone and joint disease. Semin Nucl Med 1979;9:114-20.
9. Firusian N, Mellin P, Schmidt CG. Results of strontium-89 therapy in patients with carcinoma of the prostate and incurable pain from bone metastases. J Urol 1976;116: 764-8.
10. Goeckeler WF, Edwards B, Volkert WA, Holmes CA, Simon J, Wilson D. Skeletal localization of samarium-153 chelates: potential therapeutic bone agents. J Nucl Med 1987;28:495-504.
11. 153Sm-EDTMP in the treatment of prostate cancer: a phase I/II trial. J Nucl Med 1993;34: 1839-44.
12. Serafini AN. Current status of systemic intravenous radiopharmaceuticals for the treatment of painful metastatic bone disease. Int J Radiat Oncol Biol Phys 1994;30:1187-94.
13. 153Sm Lexidronam. Drugs Aging 1997;11:413-8.
14. 153Sm-EDTMP biodistribution and dosimetry estimation. J Nucl Med 1993;34:1031-6.
15. 153Sm-EDTMP in the treatment of patients with painful bone metastases. Eur J Cancer 1997;33:1583-91.
16. Serafini AN, Houston SJ, Resche I, Quick DP, Grund FM, Ell PJ, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo controlled clinical trial. J Clin Oncol 1998;16:1574-81.
17. 153samarium EDTMP for palliation of bone pain in patients with hormone refractory prostate cancer (abstract). J Urol 1997;157(4):321.